Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alprostadil - GlobeStar Therapeutics

Drug Profile

Alprostadil - GlobeStar Therapeutics

Alternative Names: Liprostin; PGE 1; Prostaglandin E1; PROStent

Latest Information Update: 17 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Endovasc; Liprostin Inc
  • Developer Endovasc; Endovasc-TissueGen Research Sponsors; Stentgenix
  • Class Erectile dysfunction therapies; Monounsaturated fatty acids; Muscle relaxants; Peripheral vasodilators; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin E agonists; Prostaglandin E1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Peripheral vascular disorders
  • Discontinued Coronary artery restenosis; Diabetic neuropathies; Wounds

Most Recent Events

  • 14 Apr 2021 Phase II development is still ongoing for Peripheral vascular disorders in USA (AngioSoma pipeline, April 2021)
  • 12 Oct 2016 AngioSoma files for three patent applications for alprostadil in USA
  • 14 Jul 2016 Phase-II clinical trials in Peripheral vascular disorders in USA (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top